Ask Warren

SAM Chun Dang Pharm

000250 · KOSDAQ · ₩000250 · 삼천당제약

₩182,700▼ ₩5,900 (3.13%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩71B₩65B₩66B₩58B₩57B₩51B₩55B₩52B
Cost of sales₩38B₩33B₩35B₩31B₩31B₩26B₩29B₩28B
Gross profit₩33B₩32B₩32B₩27B₩26B₩25B₩26B₩24B
Operating income₩3.4B₩5.4B₩5.4B₩3.4B−₩1.1B₩688M−₩545M−₩814M
Net income−₩706M₩6.9B₩7.6B₩6.1B−₩2.9B₩1.3B−₩4.8B−₩2.1B
Net income to shareholders₩4.2B₩5.4B₩5.5B₩2.6B−₩3.3B₩478M−₩11B−₩1.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩575B₩573B₩561B₩530B₩486B₩494B₩520B₩493B
Current assets₩232B₩240B₩242B₩221B₩201B₩213B₩243B₩239B
Cash and equivalents₩63B₩84B₩96B₩103B₩81B₩83B₩106B₩134B
Total liabilities₩175B₩179B₩198B₩175B₩142B₩148B₩170B₩137B
Current liabilities₩105B₩110B₩107B₩89B₩68B₩70B₩93B₩58B
Borrowings₩48B₩45B₩45B₩46B₩46B₩46B₩45B₩56B
Total equity₩401B₩394B₩364B₩355B₩344B₩346B₩349B₩356B
Shareholders' equity₩302B₩298B₩276B₩268B₩258B₩262B₩266B₩275B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩12B−₩9.7B₩9.6B₩14B−₩15B₩1.2B₩5.3B₩4.4B
Capital spending₩10B₩13B₩13B₩21B₩5.3B₩7.4B₩2.1B₩10B
Free cash flow₩2B−₩23B−₩3B−₩6.7B−₩20B−₩6.2B₩3.2B−₩5.7B
Dividends paid₩1.2B₩0₩0₩0₩0₩4.7B₩0₩0

Consolidated where available. Amounts in won.

Also known as: SAM Chun Dang Pharm / 삼천당제약 / 000250 / KRX:000250

Source: KRX statistical information